PL3240785T3 - Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania - Google Patents
Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystaniaInfo
- Publication number
- PL3240785T3 PL3240785T3 PL15839113T PL15839113T PL3240785T3 PL 3240785 T3 PL3240785 T3 PL 3240785T3 PL 15839113 T PL15839113 T PL 15839113T PL 15839113 T PL15839113 T PL 15839113T PL 3240785 T3 PL3240785 T3 PL 3240785T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- small molecule
- lactate dehydrogenase
- molecule inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462097226P | 2014-12-29 | 2014-12-29 | |
EP15839113.6A EP3240785B1 (en) | 2014-12-29 | 2015-12-29 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
PCT/US2015/067895 WO2016109559A2 (en) | 2014-12-29 | 2015-12-29 | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3240785T3 true PL3240785T3 (pl) | 2021-12-06 |
Family
ID=55451544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL15839113T PL3240785T3 (pl) | 2014-12-29 | 2015-12-29 | Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania |
Country Status (12)
Country | Link |
---|---|
US (4) | US10351532B2 (pl) |
EP (2) | EP3954685A1 (pl) |
JP (3) | JP6903580B2 (pl) |
CN (1) | CN107624112B (pl) |
AU (2) | AU2015374118B2 (pl) |
CA (2) | CA3210002A1 (pl) |
DK (1) | DK3240785T3 (pl) |
ES (1) | ES2883938T3 (pl) |
HU (1) | HUE055662T2 (pl) |
PL (1) | PL3240785T3 (pl) |
SI (1) | SI3240785T1 (pl) |
WO (1) | WO2016109559A2 (pl) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015374118B2 (en) | 2014-12-29 | 2020-07-23 | The Trustees Of The University Of Pennsylvania | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
MX2018008815A (es) * | 2016-01-21 | 2019-03-28 | Zibo Biopolar Changsheng Pharmaceutical Co Ltd | Inhibidores de tirosina quinasa de bruton. |
WO2018005807A1 (en) * | 2016-06-29 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 1 h-pyrazol-1 -yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof |
EP3568395A1 (de) | 2017-01-10 | 2019-11-20 | Bayer Aktiengesellschaft | Heterocyclen-derivate als schädlingsbekämpfungsmittel |
CN111148743B (zh) | 2017-10-06 | 2023-12-15 | 福马治疗有限公司 | 抑制泛素特异性肽酶30 |
EP3833345A1 (en) | 2018-08-07 | 2021-06-16 | Kemijski Institut | Small molecule-inhibitors of 6-phosphofructo-1-kinase for reducing lactate generation by cancer cells |
EP3632908A1 (en) | 2018-10-02 | 2020-04-08 | Inventiva | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer |
CA3110113A1 (en) | 2018-10-05 | 2020-04-09 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors |
TWI820231B (zh) | 2018-10-11 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於製備經取代咪唑衍生物之方法 |
EP3883928A4 (en) | 2018-11-22 | 2022-06-29 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
CN114450399A (zh) * | 2019-05-02 | 2022-05-06 | 卢万天主教大学 | 用于治疗癌症的乳酸脱氢酶抑制剂多肽 |
US11725026B2 (en) * | 2019-06-28 | 2023-08-15 | The Research Foundation For The State University Of New York | Compositions and methods for inhibiting lactate dehydrogenase a activity |
WO2021026290A1 (en) | 2019-08-07 | 2021-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells having enhanced anti-tumor activity |
US11752138B2 (en) | 2020-05-18 | 2023-09-12 | Vanderbilt University | Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase |
CN115996924A (zh) * | 2020-05-18 | 2023-04-21 | 奇努克医疗加拿大公司 | 取代的吡唑基化合物及其使用方法 |
WO2021234543A1 (en) * | 2020-05-18 | 2021-11-25 | Chinook Therapeutics Canada, Inc. | Substituted pyrazolyl compounds and methods of use thereof |
WO2021251842A1 (en) * | 2020-06-08 | 2021-12-16 | Qatar Foundation For Education, Science And Community Development | Targeting of lactate dehydrogenase c, methods of preparing same, and methods of using same in combination with anti-cancer treatments |
CN116033828A (zh) | 2020-07-02 | 2023-04-28 | 拜耳公司 | 作为害虫防治剂的杂环衍生物 |
EP4255904A2 (en) * | 2020-12-03 | 2023-10-11 | Domain Therapeutics | Novel par-2 inhibitors |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5182289A (en) | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
HU217072B (hu) * | 1989-01-10 | 1999-11-29 | Pfizer Inc. | 1-Heteroaril-oxindol-3-karboxamid-származékok, azok előállítása, és az azokat tartalmazó gyógyszerkészítmények |
US5602113A (en) | 1991-02-07 | 1997-02-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridobenzo- and pyridiothieno-diazepines useful for the treatment of HIV infection |
CN1071924A (zh) | 1991-10-29 | 1993-05-12 | 纳幕尔杜邦公司 | 除草的***羧酸酰胺 |
JPH0680569A (ja) | 1992-09-03 | 1994-03-22 | Asahi Chem Ind Co Ltd | 血小板凝集阻害剤 |
US5342851A (en) | 1992-10-07 | 1994-08-30 | Mcneil-Ppc, Inc. | Substituted thiazole derivatives useful as platelet aggregation inhibitors |
DE4405207A1 (de) | 1994-02-18 | 1995-08-24 | Bayer Ag | N-Pyrazolylaniline und N-Pyrazolylaminopyridine |
US20020028936A1 (en) | 1999-04-12 | 2002-03-07 | Gerhard Sperl | 1,3-disubstituted indolin-2-ones for neoplasia |
US6136079A (en) | 1999-04-30 | 2000-10-24 | Eastman Kodak Company | Dye for ink jet ink |
AU5960300A (en) | 1999-07-15 | 2001-02-05 | Nps Allelix Corp. | Heterocyclic compounds for the treatment of migraine |
US6407238B1 (en) | 1999-10-29 | 2002-06-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process of making substituted pyrazoles |
US6436965B1 (en) | 2000-03-02 | 2002-08-20 | Merck Frosst Canada & Co. | PDE IV inhibiting amides, compositions and methods of treatment |
JP2002167531A (ja) | 2000-11-29 | 2002-06-11 | Fuji Photo Film Co Ltd | インクジェット記録用インク組成物及び画像形成方法 |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
TWI311133B (en) | 2001-04-20 | 2009-06-21 | Eisai R&D Man Co Ltd | Carboxylic acid derivativeand the salt thereof |
AU2002352148A1 (en) | 2001-06-29 | 2003-03-03 | Abbott Gmnh & Co. Kg | Bis-aryl thiazole derivatives |
IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
EP1554272B1 (en) | 2002-08-09 | 2006-10-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
US7166619B2 (en) | 2002-08-14 | 2007-01-23 | Ppd Discovery , Inc. | Prenylation inhibitors and methods of their synthesis and use |
AU2003294249A1 (en) | 2002-11-08 | 2004-06-03 | Trimeris, Inc. | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
JP2006522130A (ja) | 2003-04-03 | 2006-09-28 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としてのビアリール置換ピラゾール |
GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
WO2006036748A2 (en) | 2004-09-22 | 2006-04-06 | Symyx Technologies, Inc. | Heterocycle-amine ligands, compositions, complexes, and catalysts, and methods of making and using the same |
WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
US8097623B2 (en) | 2005-01-19 | 2012-01-17 | Biolipox Ab | Indoles useful in the treatment of inflammation |
JP2008527027A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
WO2006077365A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Indoles useful in the treatment of inflammation |
WO2006077401A1 (en) | 2005-01-19 | 2006-07-27 | Biolipox Ab | Pyrrolopyridines useful in the treatment of inflammation |
JP2008527030A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
EP1838152A2 (en) | 2005-01-21 | 2007-10-03 | Neurogen Corporation | Imidazolylmethyl and pyrazolylmethyl heteroaryl derivatives |
GB0507198D0 (en) | 2005-04-08 | 2005-05-18 | Sb Pharmco Inc | Process for preparing bicyclic compounds |
US7456292B2 (en) | 2005-06-30 | 2008-11-25 | Bexel Pharmaceuticals, Inc. | Hydroxamic acid-containing amino acid derivatives |
WO2007018508A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetycholine receptor antagonists |
WO2007018514A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
EP1922068A4 (en) | 2005-08-16 | 2010-08-11 | Icagen Inc | INHIBITORS OF VOLTAGE-CONTROLLED SODIUM CHANNELS |
WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
JP2009511462A (ja) | 2005-10-06 | 2009-03-19 | メルク シャープ エンド ドーム リミテッド | D−アミノ酸酸化酵素阻害剤として神経変性および精神疾患を治療するための縮合ピロールカルボン酸の使用 |
EP1937063A1 (en) | 2005-10-17 | 2008-07-02 | Isagro Ricerca S.r.l. | Compounds and relative use for the control of phytopathogens |
WO2007048732A1 (de) | 2005-10-28 | 2007-05-03 | Basf Aktiengesellschaft | Verwendung von 5-amino-pyrazolen zur bekämpfung pflanzenpathogener schadpilze, neue 5-amino-pyrazole, verfahren zu ihrer herstellung und sie enthaltende mittel |
ITMI20052459A1 (it) | 2005-12-22 | 2007-06-23 | Isagro Spa | Sali quaternari e relativo uso per il controllo di fitopatogeni |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
GB0614068D0 (en) | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
WO2008009924A2 (en) | 2006-07-18 | 2008-01-24 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US7906544B2 (en) | 2007-01-26 | 2011-03-15 | North Carolina State University | Inhibition of bacterial biofilms with imidazole derivatives |
WO2008121861A2 (en) | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
MX2010001462A (es) | 2007-08-27 | 2010-03-01 | Basf Se | Compuestos de pirazol para controlar plagas de invertebrados. |
US8389567B2 (en) | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
CA2719234A1 (en) | 2008-05-08 | 2009-11-12 | Joan M. Fletcher | Spiroazaindoles |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
CA2728098A1 (en) * | 2008-07-17 | 2010-01-21 | Asahi Kasei Pharma Corporation | Pyrazole-containing tricyclic compounds as_antagonits of an ep1 receptor |
AU2009272033B2 (en) * | 2008-07-17 | 2011-10-13 | Asahi Kasei Pharma Corporation | Nitrogenated heterocyclic compound |
WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
CN104211688B (zh) | 2008-09-24 | 2016-04-13 | 巴斯夫欧洲公司 | 防治无脊椎动物害虫的吡唑化合物 |
US20120245439A1 (en) * | 2008-11-20 | 2012-09-27 | David Andre | Method and apparatus for determining critical care parameters |
AU2009318098B2 (en) * | 2008-11-20 | 2015-07-16 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
CN101747276B (zh) | 2008-11-28 | 2011-09-07 | 中国中化股份有限公司 | 具有含氮五元杂环的醚类化合物及其应用 |
CA2744489C (en) | 2008-12-04 | 2015-06-23 | F.Hoffmann-La Roche Ag | Pyridazinone derivatives |
EP2367824B1 (en) | 2008-12-23 | 2016-03-23 | AbbVie Inc. | Anti-viral derivatives of pyrimidine |
WO2010111060A1 (en) | 2009-03-23 | 2010-09-30 | Merck Sharp & Dohme Corp. | P2x3, receptor antagonists for treatment of pain |
WO2010118063A2 (en) | 2009-04-06 | 2010-10-14 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
WO2011057942A1 (en) | 2009-11-12 | 2011-05-19 | Basf Se | Insecticidal methods using pyridine compounds |
US8742106B2 (en) | 2009-12-21 | 2014-06-03 | Novartis Ag | Disubstituted heteroaryl-fused pyridines |
WO2011091410A1 (en) | 2010-01-25 | 2011-07-28 | Glaxos Smithkline Llc | Trpv4 antagonists |
US8722709B2 (en) | 2010-11-10 | 2014-05-13 | Boehringer Ingelheim International Gmbh | Mineralocorticoid receptor antagonists |
JPWO2012074022A1 (ja) | 2010-12-01 | 2014-05-19 | 旭硝子株式会社 | イリジウムカチオン錯体および発光組成物 |
AR084515A1 (es) | 2010-12-22 | 2013-05-22 | Merz Pharma Gmbh & Co Kgaa | Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras |
US20120225061A1 (en) | 2011-03-04 | 2012-09-06 | Matthew Burger | Tetrasubstituted cyclohexyl compounds as kinase inhibitors |
CA2834928C (en) | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
WO2012151440A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
WO2012154880A1 (en) | 2011-05-09 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators for treating cystic fibrosis and other protein misfolding diseases |
JP2013040240A (ja) | 2011-08-11 | 2013-02-28 | Fujifilm Corp | アゾ化合物、アゾ顔料、顔料分散物、着色組成物、カラーフィルター用着色組成物、カラーフィルター、カラーフィルター用着色組成物の調製方法、インクジェット記録用インク、印刷インク、塗料、染料、及び、レジストインク |
US9115144B2 (en) | 2011-08-24 | 2015-08-25 | Kissei Pharmaceutical Co., Ltd. | Fused heterocyclic derivative and pharmaceutical use thereof |
ITPI20110143A1 (it) * | 2011-12-20 | 2013-06-21 | Univ Pisa | Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti |
PL2804861T3 (pl) | 2012-01-20 | 2018-08-31 | Genosco | Podstawione związki pirymidyny i ich zastosowanie jako inhibitory SYK |
RU2641291C2 (ru) | 2012-07-30 | 2018-01-17 | Тайсо Фармасьютикал Ко., Лтд. | Частично насыщенное азотсодержащее гетероциклическое соединение |
WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
EP2934516A4 (en) | 2012-12-20 | 2016-07-20 | Merck Sharp & Dohme | ANTAGONISTS OF 3-ESTER-4-SUBSTITUTED OREXIN RECEPTORS |
US9643955B2 (en) | 2012-12-20 | 2017-05-09 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-3-nitrile-4-substituted orexin receptor antagonists |
EP2934527A4 (en) | 2012-12-20 | 2016-07-13 | Merck Sharp & Dohme | ANTAGONIST 2-PYRYDYLOXY-4-ESTER COMPOUNDS OF OREXIN RECEPTORS |
FR3001219A1 (fr) | 2013-01-22 | 2014-07-25 | Centre Nat Rech Scient | Inhibiteurs de kinases |
PT2968440T (pt) | 2013-03-15 | 2019-07-31 | Zymeworks Inc | Compostos citotóxicos e antimitóticos e métodos de utilização dos mesmos |
US10468610B2 (en) | 2013-03-29 | 2019-11-05 | Konica Minolta, Inc. | Isomer-mixture metal complex composition, organic electroluminescent element, illuminator, and display device |
WO2014173880A1 (en) | 2013-04-22 | 2014-10-30 | Syngenta Participations Ag | Novel microbiocides |
WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
US9169221B2 (en) | 2013-04-29 | 2015-10-27 | Comsats Institute Of Information Technology | Dihydro 1,4-benzoxazines and method of synthesizing the same using sulfonium salts |
AU2015374118B2 (en) | 2014-12-29 | 2020-07-23 | The Trustees Of The University Of Pennsylvania | Small molecule inhibitors of lactate dehydrogenase and methods of use thereof |
-
2015
- 2015-12-29 AU AU2015374118A patent/AU2015374118B2/en active Active
- 2015-12-29 SI SI201531668T patent/SI3240785T1/sl unknown
- 2015-12-29 US US15/540,893 patent/US10351532B2/en active Active
- 2015-12-29 CA CA3210002A patent/CA3210002A1/en active Pending
- 2015-12-29 EP EP21181777.0A patent/EP3954685A1/en active Pending
- 2015-12-29 DK DK15839113.6T patent/DK3240785T3/da active
- 2015-12-29 JP JP2017535439A patent/JP6903580B2/ja active Active
- 2015-12-29 CA CA2978823A patent/CA2978823C/en active Active
- 2015-12-29 WO PCT/US2015/067895 patent/WO2016109559A2/en active Application Filing
- 2015-12-29 EP EP15839113.6A patent/EP3240785B1/en active Active
- 2015-12-29 PL PL15839113T patent/PL3240785T3/pl unknown
- 2015-12-29 ES ES15839113T patent/ES2883938T3/es active Active
- 2015-12-29 CN CN201580077097.9A patent/CN107624112B/zh active Active
- 2015-12-29 HU HUE15839113A patent/HUE055662T2/hu unknown
-
2019
- 2019-06-28 US US16/455,848 patent/US10961200B2/en active Active
-
2020
- 2020-10-23 AU AU2020257163A patent/AU2020257163B2/en active Active
-
2021
- 2021-01-28 US US17/160,868 patent/US11247971B2/en active Active
- 2021-06-23 JP JP2021103894A patent/JP7337883B2/ja active Active
-
2022
- 2022-01-10 US US17/572,359 patent/US11897845B2/en active Active
-
2023
- 2023-08-23 JP JP2023135162A patent/JP2023153302A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2978823A1 (en) | 2016-07-07 |
AU2020257163B2 (en) | 2022-06-30 |
US20210323928A1 (en) | 2021-10-21 |
US20180273488A1 (en) | 2018-09-27 |
JP2023153302A (ja) | 2023-10-17 |
US11247971B2 (en) | 2022-02-15 |
DK3240785T3 (da) | 2021-09-27 |
EP3954685A1 (en) | 2022-02-16 |
WO2016109559A2 (en) | 2016-07-07 |
AU2020257163A1 (en) | 2020-11-19 |
SI3240785T1 (sl) | 2021-11-30 |
US20220220078A1 (en) | 2022-07-14 |
CA2978823C (en) | 2023-10-10 |
JP6903580B2 (ja) | 2021-07-14 |
WO2016109559A3 (en) | 2016-08-25 |
JP2021152064A (ja) | 2021-09-30 |
CN107624112A (zh) | 2018-01-23 |
US20200002285A1 (en) | 2020-01-02 |
AU2015374118B2 (en) | 2020-07-23 |
EP3240785A2 (en) | 2017-11-08 |
CA3210002A1 (en) | 2016-07-07 |
AU2015374118A1 (en) | 2017-07-20 |
JP2018503631A (ja) | 2018-02-08 |
CN107624112B (zh) | 2022-03-04 |
US10961200B2 (en) | 2021-03-30 |
US11897845B2 (en) | 2024-02-13 |
HUE055662T2 (hu) | 2021-12-28 |
US10351532B2 (en) | 2019-07-16 |
EP3240785B1 (en) | 2021-07-07 |
JP7337883B2 (ja) | 2023-09-04 |
ES2883938T3 (es) | 2021-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3240785T3 (pl) | Inhibitory drobnocząsteczkowe dehydrogenazy mleczanowej i sposoby ich wykorzystania | |
IL250415B (en) | Antibodies against pd-l and methods of using them | |
IL285154A (en) | Therapeutic inhibitor of lactate dehydrogenase and their factors | |
PL3160498T3 (pl) | Cząsteczki na bazie IL-15 i sposoby ich zastosowania | |
ZA201605639B (en) | Hppd variants and methods of use | |
IL251988A0 (en) | Compounds acting on glycans and methods of using them | |
ZA201606243B (en) | Hppd variants and methods of use | |
IL259801A (en) | ezh2 inhibitors and methods of using them | |
EP3226955A4 (en) | Self-anchoring catheters and methods of use | |
SI3089971T1 (sl) | Spojine in postopki za uporabo | |
EP3190886A4 (en) | Compositions and methods of use thereof | |
EP3177327A4 (en) | Inhibitors of myh7b and uses thereof | |
SG10201709955PA (en) | Methods of treatment and compositions with xanthine oxidase inhibitors | |
EP3137873A4 (en) | Viscometer and methods of use thereof | |
EP3134108A4 (en) | Agents and methods of treatment | |
SG11201605915WA (en) | Furo-3-carboxamide derivatives and methods of use | |
ZA201606450B (en) | Compounds and their methods of use | |
HK1243404A1 (zh) | 色酰胺組合物和使用方法 | |
IL266344A (en) | Inhibitors of mtor-deptor interactions and methods of use thereof | |
EP3142999A4 (en) | Methods and compositions of dasotraline for treatment of adhd | |
GB201417248D0 (en) | Compostion and methods of treatment | |
EP3236966A4 (en) | Combination of raf inhibitors and taxanes | |
GB201403697D0 (en) | Compounds and methods of use | |
GB201416797D0 (en) | Contianer and method of use thereof | |
AU2014905067A0 (en) | Compositions and methods of use |